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Abstract 
Purpose:  To evaluate the effect of aflibercept (as second line therapy) on the clinical outcome in patients with 
chronic macular edema secondary to branch retinal vein occlusion (BRVO) insufficiently responding to prior treat-
ment with bevacizumab and/or ranibizumab.
Methods: Ten eyes of ten patients (n = 10) with chronic macular edema secondary to BRVO were included in a 
retrospective analysis. These patients received aflibercept after an insufficient response to treatment with ranibizumab 
and/- or bevacizumab. All intravitreal injections were administered according to a “treat and extend” regimen. Insuffi-
cient response was defined as the necessity of injection intervals of 6 weeks or less. The primary outcome of the study 
was the change in mean injection interval from baseline (prior switching to aflibercept) to month 12 after conversion 
to aflibercept. Secondary outcomes included the change in best corrected visual acuity (BCVA), central retinal thick-
ness (CRT), central retinal volume (CRV) and intraocular pressure (IOP).
Results: All patients completed 12 months follow-up. In total, patients received a mean of 15.5 injections of ranibi-
zumab and/or bevacizumab over a mean period of 23.1 months prior to switching to aflibercept. The primary 
endpoint indicated a significant increase in the injection interval from 5.0 weeks at baseline to 8.3 weeks at month 12 
(p = 0.002). Secondary outcomes showed favorable results. Mean BCVA increased from 72.7 letters at baseline to 77.9 
letters at month 12 after treatment initiation with aflibercept (+5.2 letters, p = 0.375). Correspondingly, CRT values 
decreased by 61.7 µm (p = 0.344) and the mean CRV (6 mm diameter) by 0.86 mm3 (p = 0.021) from baseline to 
1 year after treatment initiation with aflibercept. During the treatment period with aflibercept no significant changes 
in intraocular pressure were registered (p = 0.238).
Conclusions: Changing treatment to aflibercept in patients with chronic macular edema secondary to BRVO showed 
a statistically significant extension of the retreatment interval as well as beneficial anatomic changes in our study 
group. Our data do not allow a definite conclusion since the study was not controlled.
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Background
Among retinal vascular pathologies branch retinal 
vein occlusion (BRVO) was reported to be the second 
most common entity after diabetic retinopathy, with a 
cumulative 15-year incidence of 1.8 % [1]. BRVO mostly 
occurs at arterio-venous crossing sites, explaining the 
contribution of arteriosclerosis in adjacent arteries [2]. It 
is associated with cardiovascular risk factors and patho-
genically follows the principle of Virchow’s triad (stasis, 
hypercoagulability and endothelial damage) [3]. BRVO 
is frequently associated with macular edema (ME) as the 
endothelial damage results in an inflammatory response 
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of affected vessels with subsequent up-regulation of 
inflammatory mediators such as TNF-alpha, prosta-
glandins, leukotriens, integrins and vascular endothelial 
growth factor (VEGF) [4, 5]. Studies showed that VEGF 
plays a major role in the evolution and persistence of sec-
ondary ME [6]. Earlier treatment of ME was reported to 
be associated with better results in terms of long-term 
visual acuity [7].
For many years, the gold standard treatment for mac-
ular edema in BRVO was grid laser photocoagulation 
[8]. With the advent of anti-VEGF compounds first-line 
treatment strategies of ME in BRVO are intravitreal 
anti-VEGF agents [ranibizumab (Lucentis ©, Novartis), 
bevacizumab (Avastin ©, Genentech) and afliber-
cept (Eylea ©, Regeneron Pharmaceuticals Inc.)]. In 
comparison to grid laser photocoagulation, the use of 
aflibercept led to a significant visual benefit and reduc-
tion in central retinal thickness (CRT) in eyes with 
macular edema secondary to BRVO as reported in the 
VIBRANT study [9].
Aflibercept, the most recently developed anti-VEGF 
agent, is a 115-kDa soluble receptor fusion protein con-
sisting of the second domain of VEGF receptor 1 and the 
third domain of VEGF receptor 2 fused to the Fc domain 
of immunoglobulin G1. In contrast to other anti-VEGF 
agents, aflibercept additionally binds PGF (placental 
derived growth factor) and has a considerably higher 
binding affinity for VEGF [10, 11]. Furthermore a longer 
duration of action was reported, which contributed to 
the recent approval for macular edema in CRVO [12]. 
Experience with aflibercept in patients with CRVO and 
ME insufficiently responding to prior anti-VEGF showed 
favorable outcomes [13, 14].
The current study was designed to evaluate the change 
of injection interval and clinical outcomes in patients 
who have been treated with aflibercept for at least 
12 months as a consequence of an insufficient response 
to ranibizumab and/or bevacizumab.
Methods
This retrospective clinical study was conducted at the 
department of ophthalmology, City hospital Triemli 
Zurich and was approved by the local ethics committee 
(Ethics Commission of the Canton Zurich, KEK-ZH-Nr. 
2014-0601). Its conduction adhered to the tenets of the 
declaration of Helsinki. Included patients (n =  10) gave 
their written informed consent on retrospective data 
evaluation and its publication. Data were retrieved from 
an internal database, containing clinical information of 
all patients treated with anti-VEGF agents during the 
past 3 years (2012–2015). In addition medical charts and 
optical coherence tomography scans (OCT) of included 
patients were reviewed.
Patients of Caucasian descent in whom therapy was 
changed to off-label aflibercept as an individual case 
decision, after an insufficient response to treatment with 
bevacizumab or ranibizumab, were included in this case 
series. Insufficient response was defined as the necessity 
of injection intervals of 6  weeks or less, elicited by the 
persistence or any increase of intraretinal fluid as imaged 
by spectral-domain optical coherence tomography (Hei-
delberg Spectralis © System). Evidence of increasing 
or persistent fluid in any of the 19 standard scans (512 
A—scans, 20°  ×  15°) was considered as disease-related 
activity.
All intravitreal injections were administered accord-
ing to a “treat and extend” regimen [15]. This protocol is 
characterized by the adjustment of individual injection 
intervals according to therapeutic response. The main 
objective of this protocol is to reduce the treatment bur-
den for the patient, considering risks and inconveniences 
each injection carries, as well as economic aspects. At 
each visit OCT scans were evaluated for alterations of 
intraretinal and subretinal fluid. The absence of any activ-
ity sign (increasing and/or persistent fluid) resulted in a 
prolongation of the current injection interval by 2 weeks 
and vice versa.
The primary outcome was the change in the mean 
injection interval comparing baseline (prior to treatment 
with aflibercept) to month 12 after switching to afliber-
cept. Secondary outcomes included: best-corrected visual 
acuity (BCVA), central retinal thickness (CRT), central 
retinal volume (CRV) (6  mm diameter, 512 A—scans, 
20° × 15°) and intraocular pressure (IOP, as measured by 
air-puff tonometry). For statistical purposes, visual acu-
ity measures (registered as Snellen acuity fractions) were 
converted into ETDRS scores (Early Treatment Diabetic 
Retinopathy Study) as described by Gregori et  al. [16]. 
Information on CRT and CRV was retrieved from spec-
tral- domain optical coherence tomography (SD-OCT) 
scans (Heidelberg Spectralis © System, Heidelberg Engi-
neering). OCT images at month 6 and 12 were taken 
using the SLO-based (scanning laser ophthalmoscope) 
eye tracking system (AutoRescan), ensuring the correct 
location for follow-up.
Statistical analyses were performed using SPSS® Ver-
sion 20 and Microsoft Office Excel for Windows, Ver-
sion 2007. Binomial and exact Wilcoxon signed rank tests 
were employed for asymmetrical (visual acuity, central 
retinal thickness and volume, injection interval) and sym-
metrical (IOP) distributions of differences, respectively.
Results
Ten eyes (n  =  10) of ten patients with macular edema 
secondary to BRVO were included in the current ret-
rospective analysis. These patients received aflibercept 
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after an initial insufficient response (criteria see above) to 
treatment with ranibizumab and/or bevacizumab.
The study group consisted of 8 male and 2 
female patients. Mean age at baseline amounted to 
73.9 ± 5.2 years.
Eight patients were pretreated with ranibizumab, 1 
patient was pretreated with bevacizumab intravitreal 
injections and 1 patient was pretreated with both anti-
VEGF agents. At baseline (pre-aflibercept), patients 
had received a mean of 15.5 (SD ± 5.02) injections dur-
ing a mean period of 23.1 (SD  ±  13.8) months (range 
10–53 months). During the 10–12 months prior switch-
ing treatment to aflibercept, included patients received a 
mean of 10.0 injections.
The mean injection interval—as primary outcome—
increased from 5.0  ±  1.6  weeks at baseline (prior 
therapy change) to 8.5  ±  3.3  weeks at month 6 and 
8.3  ±  2.1  weeks at month 12 (p  =  0.002) (Fig.  1). This 
resulted in a mean prolongation of 3.3  ±  1.8  weeks 
throughout the observation period.
As functional and secondary outcome, BCVA fluctu-
ated from 72.7 ±  15.2 letters at baseline to 72.2 ±  15.2 
letters at month 6 and 77.9  ±  6.8 letters at month 
12 (Fig.  2). The gain of 5.2 (SD  ±  11.0) letters after 
12  months did not reach the level of statistical sig-
nificance (p =  0.375). From initial diagnosis to baseline 
(therapy switch to aflibercept) a mean gain of 10.3 ± 11.0 
letters was measured.
Secondary anatomical outcomes, such as the mean 
CRT and mean CRV likewise indicated an improve-
ment. Pretreatment CRT amounted to 453.8 ± 122.2 µm. 
CRT decreased from 373.2  ±  195.1  µm at baseline to 
351.0  ±  226.9  µm at month 6 and 311.5  ±  95.1  µm at 
month 12. The mean reduction of 61.7  µm  ±  192.1 
did not reach the level of statistical significance 
(p = 0.344) (Fig. 3). Analogously, CRV was reduced from 
9.5 ± 1.9 mm3 at baseline to 9.4 ± 2.7 mm3 at month 6 
and 8.6 ± 1.1 mm3 at month 12. This resulted in a mean 
reduction of 0.9 ± 2.4 mm3 within the treatment period 
of 12 months (p = 0.021). Pretreatment values amounted 
to 11.2 ± 3.1 mm3 (Fig. 4).
Intraocular pressure values were not significantly 
affected by aflibercept intravitreal injections during the 
study period (p = 0.238).
Discussion
Our data indicate that by switching anti-VEGF therapy 
to aflibercept in eyes with chronic, recurrent ME due to 
BRVO a significant extension of the injection interval 
can be obtained. Our data do not allow a definite con-
clusion since the study was not controlled and included 
only a small number of patients. However, it appears 
rather unlikely that a chronic recurrent ME in BRVO 
shows on average almost half the need for treatment 
within 6  months (extension of treatment intervals by a 
mean of 3.5 weeks). Nevertheless, the substantive range 
Fig. 1 Injection interval (median, SD): change from baseline to 
month 12 (p = 0.002)
Fig. 2 Visual acuity (median, SD): change from baseline to month 12 
(p = 0.375)
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of injection intervals (±3.3 weeks) at month 12 must be 
considered concerning this matter. The further follow-up 
(month 6–12) showed no further relevant change in the 
treatment interval, indicating that rather the change in 
therapy than a continuous regression of disease activity 
is the origin of extended treatment intervals. A sponta-
neous regression in the natural course of macular edema 
secondary to BRVO as described by Rogers et  al. [17] 
appears rather unlikely since patients with recurrent 
chronic ME were selected.
The rationale for this finding is likely related to different 
properties of aflibercept (higher VEGF binding affinity, 
additional PGF binding) compared to ranibizumab and 
bevacizumab [10, 11]. Recently presented data demon-
strated the longest intravitreal retention time for afliber-
cept in comparison to bevacizumab and ranibizumab 
[18]. Analysis of intraocular VEGF levels in humans fol-
lowing intravitreal aflibercept administration indicated 
that VEGF was suppressed below the lower limit of quan-
tification for 10 weeks on average [19].
Functional and anatomic outcomes (CRT, CRV, 
BCVA) showed some improvement during the whole 
study period after therapy change to aflibercept (base-
line to month 12). However, only a minority of param-
eters showed statistically significant changes. This has to 
be seen in the context that all eyes had been extensively 
treated prior to change of therapy and that they had a 
significant increase in their visual acuity (+10.3 letters) 
from prior to any therapy to baseline. Therefore, the 
additional potential functional and anatomic gain already 
was limited.
Since only two patients were pretreated with bevaci-
zumab, comparison of outcomes between the two types 
of anti-VEGF pretreatments (ranibizumab/bevacizumab) 
was not judged as expedient in our analysis.
Due to lack of data for aflibercept in BRVO, no com-
parison with existing studies can be made. Pfau et  al. 
indicate superior results of aflibercept in CRVO as com-
pared to prior ranibizumab/bevacizumab treatment 
[13]. Since edema secondary to BRVO in the major-
ity of cases is less pronounced than in CRVO, a less 
measurable improvement following treatment may be a 
consequence.
Conclusions
In conclusion, our retrospective analysis showed a statis-
tically significant and clinically relevant prolongation of 
injection intervals within 12 months following a change 
of anti-VEGF therapy in patients with chronic recurrent 
ME secondary to BRVO. However, improvements regard-
ing BCVA and CRT were limited. Larger prospective, 
clinical trials are required not only to confirm less need 
for treatment with aflibercept, but also to clearly dem-
onstrate a functional and anatomic benefit by changing 
anti-VEGF agents.
Fig. 3 Central retinal thickness (mean, SD): change from baseline to 
month 12 (p = 0.344)
Fig. 4 Central retinal volume (mean, SD): change from baseline to 
month 12 (p = 0.021)
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Limitations
The small number of patients, the lack of a control group 
and the retrospective study design not only inhere the 
risk of type 1 and type 2 errors, but also of selection and 
performance bias. Moreover, interobserver variability 
must be mentioned as a potential source of bias.
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